Abstract
Mitochondrial biogenesis (MB) is the essential mechanism by which cells control the number of mitochondria. Cells respond to different physiologic, metabolic, and pathologic changes by regulating this organelle with high morphological and functional adaptability. A considerable number of proteins, transcription factors, upstream regulatory proteins and secondary mechanisms are involved in MB and the stabilization of new mitochondrial DNA. These MB activators and regulators, including the main participating proteins (e.g. PGC-1α and mtTFA), are candidates for therapeutic intervention in diverse diseases, like neurodegenerative disorders, metabolic syndrome, sarcopenia, cardiac pathophysiology and physiological processes like aging. In this review, we analyze the implication of MB in several diseases in which the MB pathway is affected. Furthermore, we describe therapeutical interventions on MB targets to boost MB for the prevention and treatment of human diseases. Furthermore, evidence based results and the knowledge gained during last years for some of these drugs aim us hypothesize about the value of a given treatment involved in the activation of MB.
Keywords: Aging, sarcopenia, metabolic syndrome, renal diseases, cardiac diseases, neurodegenerative diseases.
Current Pharmaceutical Design
Title:Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Volume: 20 Issue: 35
Author(s): Fabian Sanchis-Gomar, Jose Luis Garcia-Gimenez, Mari Carmen Gomez-Cabrera and Federico V. Pallardo
Affiliation:
Keywords: Aging, sarcopenia, metabolic syndrome, renal diseases, cardiac diseases, neurodegenerative diseases.
Abstract: Mitochondrial biogenesis (MB) is the essential mechanism by which cells control the number of mitochondria. Cells respond to different physiologic, metabolic, and pathologic changes by regulating this organelle with high morphological and functional adaptability. A considerable number of proteins, transcription factors, upstream regulatory proteins and secondary mechanisms are involved in MB and the stabilization of new mitochondrial DNA. These MB activators and regulators, including the main participating proteins (e.g. PGC-1α and mtTFA), are candidates for therapeutic intervention in diverse diseases, like neurodegenerative disorders, metabolic syndrome, sarcopenia, cardiac pathophysiology and physiological processes like aging. In this review, we analyze the implication of MB in several diseases in which the MB pathway is affected. Furthermore, we describe therapeutical interventions on MB targets to boost MB for the prevention and treatment of human diseases. Furthermore, evidence based results and the knowledge gained during last years for some of these drugs aim us hypothesize about the value of a given treatment involved in the activation of MB.
Export Options
About this article
Cite this article as:
Sanchis-Gomar Fabian, Garcia-Gimenez Luis Jose, Gomez-Cabrera Carmen Mari and Pallardo V. Federico, Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches, Current Pharmaceutical Design 2014; 20 (35) . https://dx.doi.org/10.2174/1381612820666140306095106
DOI https://dx.doi.org/10.2174/1381612820666140306095106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Light Chain Amyloidosis – Current Findings and Future Prospects
Current Protein & Peptide Science Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews Mechanism-based Modulator Discovery for Sirtuin-catalyzed Deacetylation Reaction
Mini-Reviews in Medicinal Chemistry Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Current Neuropharmacology The LIM Protein fhlA is Essential for Heart Chamber Development in Zebrafish Embryos
Current Molecular Medicine Statins and Oxidative Stress in the Cardiovascular System
Current Pharmaceutical Design A Review on the Sex Differences in Organ and System Pathology with Alcohol Drinking
Current Drug Abuse Reviews Stiff Left Atrial Syndrome; Prospects and Possibilities. Retrospective Analysis and Review of the Literature
Current Hypertension Reviews Antiarrhythmic Potential of Drugs Targeting the Cardiac Ryanodine Receptor Ca<sup>2+</sup> Release Channel: Case Study of Dantrolene
Current Pharmaceutical Design Mn-SOD and Chronic Inflammation of Gastric Mucosa
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Effects of Green Tea on Iron Accumulation and Oxidative Stress in Livers of Iron-Challenged Thalassemic Mice
Medicinal Chemistry Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Diabetes and Metallothionein
Mini-Reviews in Medicinal Chemistry Metabolic Therapy of Heart Failure
Current Pharmaceutical Design